Caligan Partners LP

All Holdings — 2025 Q4

AI Portfolio Summary
In 2025 Q4, Caligan Partners LP maintained a portfolio of 30 distinct positions. The most significant new addition to the portfolio was MINERALYS THERAPEUTI, which now represents 6.87% of the total fund value. They heavily accumulated shares in REVOLUTION MEDICINES, increasing their position by 20.6%. Conversely, Caligan Partners LP completely exited their position in AGIOS PHARMACEUTICAL.
PCA Score Concentration Risk
Risk ENB
Total Positions
30
Quarter
2025 Q4
Top Holding
LQDA (23.1%)
Top 10 Concentration
84.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 30
Stock History Sector / Type Port % Prev % Rank / Prev Conviction Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
LQDA
LIQUIDIA CORPOR...
Healthcare 23.05% 24.18% #1
Prev: #1
9.2 no change no change
P
S
8,118,892 $280,020,585 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
ABVX
ABIVAX SA
Healthcare 16.12% 16.14% #2
Prev: #2
6.4 no change no change
P
S
1,451,924 $195,799,211 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
RVMD
REVOLUTION MEDI...
Healthcare 8.42% 6.51% #3 2
Prev: #5
5.4 219,651 20.6%
P
S
1,283,900 $102,262,635 2025 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
MLYS
MINERALYS THERA...
Healthcare 8.28% 13.77% #4 1
Prev: #3
3.3 no change no change
P
S
2,772,654 $100,619,614 2024 Q2 13F Filing 2025-12-31 2026-02-14 (Est.)
MLYS
MINERALYS THERA...
PUT
PUT Option 6.87% #5
Prev: #—
4.7 2,298,400 no change
NEW
2,298,400 $83,408,936 2024 Q2 13F Filing 2025-12-31 2026-02-14 (Est.)
PCVX
VAXCYTE INC
Healthcare 6.48% #6
Prev: #—
4.6 1,704,815 no change
NEW
1,704,815 $78,660,164 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
EXEL
EXELIXIS INC
Healthcare 5.60% 8.25% #7 3
Prev: #4
4.2 27,532 1.8%
P
S
1,553,262 $68,079,473 2023 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
ADMA
ADMA BIOLOGICS ...
Healthcare 4.52% 5.06% #8
Prev: #8
3.9 375,899 14.3%
P
S
3,012,508 $54,948,146 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
TNGX
TANGO THERAPEUT...
Healthcare 2.72% #9
Prev: #—
3.1 3,729,895 no change
NEW
3,729,895 $33,046,870 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
INBX
INHIBRX BIOSCIE...
Healthcare 2.10% 1.04% #10 5
Prev: #15
3.0 87,182 36.9%
P
S
323,565 $25,561,635 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
TYRA
TYRA BIOSCIENCE...
Healthcare 2.04% 1.28% #11 3
Prev: #14
2.9 247,432 35.5%
P
S
944,257 $24,824,517 2025 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
XENE
XENON PHARMACEU...
PUT
PUT Option 2.03% #12
Prev: #—
2.8 549,700 no change
NEW
549,700 $24,637,554 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
XENE
XENON PHARMACEU...
Healthcare 2.03% 2.34% #13 2
Prev: #11
2.9 105,100 23.6%
P
S
549,665 $24,635,985 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
MAZE
MAZE THERAPEUTI...
Healthcare 1.88% #14
Prev: #—
2.8 550,191 no change
NEW
550,191 $22,794,413 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
RAPT
RAPT THERAPEUTI...
Healthcare 1.80% #15
Prev: #—
2.7 644,400 no change
NEW
644,400 $21,825,828 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
AVTX
AVALO THERAPEUT...
Healthcare 1.32% 1.39% #16 3
Prev: #13
2.5 48,200 5.8%
P
S
881,533 $16,008,639 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
ANIK
ANIKA THERAPEUT...
Healthcare 1.14% 1.77% #17 5
Prev: #12
0.5 no change no change
P
S
1,435,130 $13,791,599 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
INBX
INHIBRX BIOSCIE...
CALL
CALL Option 0.98% #18
Prev: #—
2.4 150,000 no change
NEW
150,000 $11,850,000 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
VOR
VOR BIOPHARMA I...
Healthcare 0.82% #19
Prev: #—
2.3 925,067 no change
NEW
925,067 $9,962,972 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
IVA
INVENTIVA SA
Healthcare 0.77% #20
Prev: #—
2.3 2,000,000 no change
NEW
2,000,000 $9,300,000 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
VRCA
VERRICA PHARMAC...
Healthcare 0.63% 0.52% #21 5
Prev: #16
0.3 no change no change
P
S
923,910 $7,677,692 2023 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
AGIO
AGIOS PHARMACEU...
CALL
CALL Option 0.20% #22
Prev: #—
2.1 90,000 no change
NEW
90,000 $2,449,800 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
SPRB
SPRUCE BIOSCIEN...
Healthcare 0.15% #23
Prev: #—
2.1 20,514 no change
NEW
20,514 $1,786,975 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
ELDN
ELEDON PHARMACE...
Healthcare 0.07% #24
Prev: #—
2.0 555,978 no change
NEW
555,978 $839,527 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
AGIO
AGIOS PHARMACEU...
Healthcare 0.00% 5.95%
Sold All 😨
(Was: #6)
0.3 -1,131,205 -100.0%
CLOSED
$— 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
AGIO
AGIOS PHARMACEU...
PUT
PUT Option 0.00% 5.13%
Sold All 😨
(Was: #7)
0.3 -975,000 -100.0%
CLOSED
$— 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
EOLS
EVOLUS INC
Healthcare 0.00% 3.33%
Sold All 😨
(Was: #9)
0.3 -4,138,943 -100.0%
CLOSED
$— 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
MRUS
MERUS N V
Healthcare 0.00% 2.68%
Sold All 😨
(Was: #10)
0.3 -216,954 -100.0%
CLOSED
$— 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
SLS
SELLAS LIFE SCI...
CALL
CALL Option 0.00% 0.48%
Sold All 😨
(Was: #17)
0.3 -2,300,000 -100.0%
CLOSED
$— 2025 Q2 13F Filing 2025-12-31 2026-02-14 (Est.)
AURA
AURA BIOSCIENCE...
Healthcare 0.00% 0.18%
Sold All 😨
(Was: #18)
0.3 -227,174 -100.0%
CLOSED
$— 2025 Q2 13F Filing 2025-12-31 2026-02-14 (Est.)
Showing 1-25 of 30 holdings

Unlock Full Caligan Partners LP Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics